Lenmeldy is an autologous hematopoietic stem cell-based gene therapy. It was approved in 2024 by the FDA; the European Commission approved it in 2020 (as Libmeldy).
Read moreEmployers with self-funded health plans are faced with controlling escalating claims costs while prioritizing employee care.
Read moreEmployees need an advocate to make decisions that lead to better health for themselves and better financial outcomes for everyone.
Read moreOn December 8, 2023, the US Food and Drug Administration (FDA) approved two groundbreaking treatments.
Read more